Orexo, GAIA to develop digital therapeutic for opioid use disorder
By Paul Bonanos, Associate Editor | Aug 21, 2019 | 9:48 PM GMT
Via a deal with German digital therapeutics company GAIA, Orexo will develop a psychosocial support product intended to enhance the use of Zubsolv buprenorphine/naloxone, its treatment for opioid use disorder (OUD).
Read the full 317 word article
User Sign In
This article may not be distributed to non-subscribers
PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD